Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections

Nicholas Rebold; Taylor Morrisette; Abdalhamid M Lagnf; Sara Alosaimy; Dana Holger; Katie Barber; Julie Ann Justo; Kayla Antosz; Travis J Carlson; Jeremy J Frens; Mark Biagi; Wesley D Kufel; William J Moore; Nicholas Mercuro; Brian R Raux; Michael J Rybak

doi:10.1093/ofid/ofab554

Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections

Open Forum Infect Dis. 2021 Dec 9;8(12):ofab554. doi: 10.1093/ofid/ofab554. eCollection 2021 Dec.

Authors

Nicholas Rebold¹, Taylor Morrisette^{1

2

3}, Abdalhamid M Lagnf¹, Sara Alosaimy¹, Dana Holger¹, Katie Barber^{4

5}, Julie Ann Justo^{6

7}, Kayla Antosz⁷, Travis J Carlson⁸, Jeremy J Frens⁹, Mark Biagi^{10

11}, Wesley D Kufel^{12

13}, William J Moore¹⁴, Nicholas Mercuro^{15

16}, Brian R Raux², Michael J Rybak^{1

17

18}

Affiliations

¹ Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
² Department of Pharmacy Services, Medical University of South Carolina, Charleston, South Carolina, USA.
³ Department of Pharmacy & Outcomes Sciences, Medical University of South Carolina College of Pharmacy, Charleston, South Carolina, USA.
⁴ Department of Pharmacy, University of Mississippi Medical Center, Jackson, Mississippi, USA.
⁵ Department of Pharmacy Practice, University of Mississippi School of Pharmacy, Jackson, Mississippi, USA.
⁶ Clinical Pharmacy and Outcomes Sciences, University of South Carolina College of Pharmacy, Columbia, South Carolina, USA.
⁷ Department of Pharmacy, Prisma Health-Midlands, Columbia, South Carolina, USA.
⁸ Department of Clinical Sciences, Fred Wilson School of Pharmacy, High Point University, High Point, North Carolina, USA.
⁹ Department of Pharmacy, Moses H. Cone Memorial Hospital, Cone Health, Greensboro, North Carolina, USA.
¹⁰ College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA.
¹¹ Department of Pharmacy, Swedish American Health System, Rockford, Illinois, USA.
¹² Department of Pharmacy Practice, Binghamton University School of Pharmacy and Pharmaceutical Sciences, Binghamton, New York, USA.
¹³ Department of Medicine, State University of New York Upstate Medical University, Syracuse, New York, USA.
¹⁴ Department of Pharmacy, Northwestern Memorial Hospital, Chicago, Illinois, USA.
¹⁵ Department of Pharmacy, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
¹⁶ Department of Pharmacy, Maine Medical Center, Portland, Maine, USA.
¹⁷ Department of Pharmacy Services, Detroit Medical Center, Detroit, Michigan, USA.
¹⁸ Division of Infectious Diseases, Department of Medicine, School of Medicine, Wayne State University, Detroit, Michigan, USA.

Abstract

A multicenter case series of 21 patients were treated with imipenem-cilastatin-relebactam. There were mixed infection sources, with pulmonary infections (11/21,52%) composing the majority. The primary pathogen was Pseudomonas aeruginosa (16/21, 76%), and 15/16 (94%) isolates were multidrug-resistant. Thirty-day survival occurred in 14/21 (67%) patients. Two patients experienced adverse effects.

Keywords: Pseudomonas aeruginosa; carbapenem-resistant Enterobacterales; imipenem-cilastatin-relebactam; multidrug-resistant.